Skip to main content
OpenTrials
Completed

NCT Number: NCT02919475

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying anti-rheumatic drug therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

La Plata, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of RA prior to the Screening Visit.
  • Active disease despite ongoing therapy with up to two non-biologic disease-modifying anti-rheumatic drugs, including methotrexate at both the Screening and Baseline Visits.
  • Screening hs-CRP ≥1.2 x upper limit of normal (ULN).

Exclusion criteria

  • Prior/current exposure to biologic and/or kinase inhibitor therapy.
  • Known history or presence of polyneuropathy of any cause and no presence of clinically active compression neuropathy, radiculopathy or plexopathy at the Screening Visit.
  • Positive test results for human immunodeficiency (HIV) virus, hepatitis B virus or hepatitis C (HCV) virus at the Screening Visit.
  • Positive drug of abuse and alcohol test results.
  • History of a clinically-significant infection that required oral antimicrobial or antiviral therapy within 8 weeks prior to Day 1.

Treatment and study plan

JTE-051

Drug

Active drug tablets containing JTE-051

Placebo

Drug

Placebo tablets identical in appearance to the active drug tablets

Primary outcomes

  1. Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)

    Time frame: Up to 12 Weeks

    Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo.

    The ACR core set measures are:

    • Tender joint count
    • Swollen joint count
    • Subject Assessment of arthritis pain
    • Subject's Global Assessment of disease activity (SGA)
    • Physician's Global Assessment of disease activity (PGA)
    • Health Assessment Questionnaire Disability Index (HAQ-DI)
    • Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

Secondary outcomes

  1. Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12

    Time frame: Week 12

    Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.

    The ACR core set measures are:

    • Tender joint count
    • Swollen joint count
    • Subject Assessment of arthritis pain
    • Subject's Global Assessment of disease activity (SGA)
    • Physician's Global Assessment of disease activity (PGA)
    • Health Assessment Questionnaire Disability Index (HAQ-DI)
    • Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

  2. Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12

    Time frame: Week 12

    Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.

    The ACR core set measures are:

    • Tender joint count
    • Swollen joint count
    • Subject Assessment of arthritis pain
    • Subject's Global Assessment of disease activity (SGA)
    • Physician's Global Assessment of disease activity (PGA)
    • Health Assessment Questionnaire Disability Index (HAQ-DI)
    • Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

  3. Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12

    Time frame: Week 12

    Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.

    The ACR core set measures are:

    • Tender joint count
    • Swollen joint count
    • Subject Assessment of arthritis pain
    • Subject's Global Assessment of disease activity (SGA)
    • Physician's Global Assessment of disease activity (PGA)
    • Health Assessment Questionnaire Disability Index (HAQ-DI)
    • Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)

  4. Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12

    Time frame: Week 12

    The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows:

    0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity

  5. Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12

    Time frame: Week 12

    The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows:

    0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity

  6. Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12

    Time frame: Week 12

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula:

    DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*SGA+0.96.

    DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP <2.6.

    A decrease in DAS28-CRP indicated an improvement in participant's condition.

  7. Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12

    Time frame: Week 12

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

  8. Number of Subjects With Treatment-related Adverse Events

    Time frame: Up to 16 Weeks

    Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.

  9. Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12

    Time frame: Week 12

Sponsors and collaborators

Lead sponsor

Akros Pharma Inc.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)

Acronym: MOVE-RA

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Sep 29, 2016
Registry last updated
Jun 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.